انتكاسة التهاب الدماغ بأجسام مضادة لمستقبلات NMDA لدى الأطفال دون 18 عامًا

References

1. Return of previous resolved symptoms and signs, or appearance of new symptoms or signs, associated with change in function, lasting more than 1 wk (or shorter if associated with change in safety), that cannot be explained by adverse reactions to current medications or intercurrent illness, after a period of stability or improvement of at least 1 mo.
2. First-line immunotherapy should be offered to all children with NMDARE relapse, even if they are improving at the time of diagnosis (i.e., late diagnosis or rapid improvement and remission). First-line immunotherapy and combinations can be used as per Table 2, 2.2.